Trial intelligence / Profile preview

Phase I/II study of TAK-788 in metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

CTR20190582Phase 2Active

Sponsor

Millennium Pharmaceuticals

Start

Jul 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1